Navamedic sells chitin operation - Focus on core strategy
ChitiNor contributed to the EBITDA of Navamedic with NOK -1.4 million in 2007 and with NOK -0.4 million in Q1 2008. In addition, the cost of owning and managing ChitiNor has been estimated to be around NOK 0.15 million per quarter. A NOK 1.65 million write down is made in Q1 to reflect the sales price of ChitiNor AS.
Navamedic retains the ownership of its proprietary glucosamine production method. Should it see it financially beneficial, Navamedic may utilize this technology to reduce raw material costs.
The former Chairman of the Board in Navamedic, Thorleif Thormodsen, is a minority share holder and a board member in Seagarden AS.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.